In the Original Investigation titled “Characteristics of Oncology Clinical Trials: Insights From a Systematic Analysis of ClinicalTrials.gov,” published online on April 29 and also in the June 10 issue of JAMAInternal Medicine (2013;173[11]:972-979. doi:10.1001/jamainternmed.2013.627), incorrect information appeared in the text. On page 977, in the Limitations and the Need for Better Reporting Standards subsection of the Discussion, the second sentence of the first paragraph, which read “There are limits to the registry’s completeness, because registration is required only for studies that had been initiated as of October 2007 and met all 4 of the following criteria: (1) interventional study of drugs, biologics, or devices; (2) trial phase 2, 3, or 4; (3) inclusion of at least 1 US site; and (4) trial conducted under an investigational new drug application or investigational device exemption.” should be replaced with the following sentence: “There are limits to the registry’s completeness, because registration is required only for studies that had been initiated as of October 2007 and met the following criteria: (1) interventional study of drugs, biologics, or devices; (2) trial phase 2, 3, or 4; (3) inclusion of at least 1 US site or trial conducted under an investigational new drug application or investigational device exemption.” This article was corrected online.
↧